[Chinese consensus on autologous stem cell transplantation for adult acute leukemia (2024)]

Abstract

Autologous stem cell transplantation (ASCT) emerges as a therapeutic strategy following remission in adult acute leukemia (AL). It offers advantages over allogeneic hematopoietic stem cell transplantation (allo-HSCT), including independence from donor availability, absence of graft-versus-host disease (GVHD), and a reduced risk of transplant-related mortality. Furthermore, when juxtaposed with the extended regimens of consolidation chemotherapy, ASCT stands out by markedly abbreviating treatment duration, alleviating the economic strain on patients, and enhancing their overall quality of life. Despite these benefits, the adoption of ASCT among adult AL patients in China remains disproportionately low. To enhance clinical physicians' understanding of the role and position of ASCT in AL management and to improve the clinical efficacy of ASCT, it is urgent to establish a consensus among experts on ASCT for adult acute leukemia in our nation.

图1. 成人急性髓系白血病（AML）患者自体造血干细胞移植（auto-HSCT）的适应证选择–,–

注 APL：急性早幼粒细胞白血病；CR1、CR2：第1、2次完全缓解；MRD：微小残留病

图2. 成人急性淋巴细胞白血病（ALL）自体造血干细胞移植（auto-HSCT）的适应证选择,–

注 Ph：费城染色体；CR1：第1次完全缓解；MRD：微小残留病